Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) represent an unmet
clinical need whose prognosis is still dismal. Alterations of immune response play a …

In recent decades, therapy for acute myeloid leukemia (AML) has remained relatively
unchanged, with chemotherapy regimens primarily consisting of an induction regimen …

Background: Therapy options for pts with HR-MDS or AML who are not candidates for
intensive chemotherapy (IC) or hematopoietic stem cell transplantation (HSCT) are limited …

Background: Sabatolimab (MBG453) is a high-affinity, humanized, IgG4 (S228P) antibody
targeting TIM-3, an inhibitory receptor that regulates adaptive and innate immune …

Therapeutic monoclonal antibodies (mAbs) such as antibody-drug conjugates, ligand-
receptor antagonists, immune checkpoint inhibitors and bi-specific T cell engagers have …

Patients with higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic
leukemia (CMML) unfit for hematopoietic stem cell transplantation have poor outcomes …

Abstract Purpose of Review The advent of several targeted agents has revolutionized the
treatment of acute myeloid leukemia (AML) in recent times; however, majority of patients are …

Background: Pts with higher-risk MDS and AML need treatment options that provide durable
responses with sustained clinical benefit and favorable safety/tolerability. Sabatolimab is a …

There has been long-standing interest in using monoclonal antibodies to improve outcomes
of people with acute myeloid leukemia (AML). While several candidate therapeutics have …

Over the past decade, monoclonal antibodies have dramatically impacted the treatment of
haematological malignancies, as evidenced by the effect of rituximab on the response rate …